Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion type Assertion NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_head.
- NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion description "[In human lung adenocarcinomas harboring EGFR mutations, a second-site point mutation that substitutes methionine for threonine at position 790 (T790M) is associated with approximately half of cases of acquired resistance to the EGFR kinase inhibitors, gefitinib and erlotinib.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_provenance.
- NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion evidence source_evidence_literature NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_provenance.
- NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion SIO_000772 18093943 NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_provenance.
- NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion wasDerivedFrom befree-2016 NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_provenance.
- NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_assertion wasGeneratedBy ECO_0000203 NP646294.RAXpAtjpm3nx6lo5NjUC9phB55qixpfJYiWY-HAkEREb4130_provenance.